<DOC>
	<DOCNO>NCT01174433</DOCNO>
	<brief_summary>To assess safety feasibility use Tryton bifurcation coronary stent system treatment single de novo bifurcation lesion native coronary artery .</brief_summary>
	<brief_title>Safety Study Assess FEasibility Use TRYTON Bifurcation Coronary Stent System ( SAFE-TRY )</brief_title>
	<detailed_description>Currently available stent design straight lesion , optimise provide scaffold ( coverage radial strength ) ease deliverability . In straight lesion , stent show provide superb acute long-term result . One lesion subset continue challenge interventionalist bifurcation lesion . A number different strategy employ standard stent address bifurcation lesion significant limitation . Large contemporary registry characterise current stent usage bifurcate lesion demonstrate decreased procedural success increase rate restenosis thrombosis ( acute , subacute delayed ) . The limitation currently available stent lead group develop stent design specifically treat bifurcation lesion . The Tryton Side-Branch Stent Stent TM ( Tryton Medical , Inc. , Newton , MA , USA ) balloon expandable cobalt chromium stent , design specifically treat bifurcation lesion . The primary objective study evaluate safety feasibility use Tryton bifurcation coronary stent system treatment single de novo bifurcation lesion native coronary artery reference vessel diameter ( RVD ) proximal main vessel 2.5 - 5.0 mm , distal main branch 2.5 - 5.0 mm , side branch RVD 2.5 - 3.5 mm .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>General Inclusion Criteria Candidate percutaneous coronary intervention &amp; emergent coronary artery bypass graft surgery Clinical evidence ischemic heart disease positive functional study Female patient childbearing potential negative pregnancy test within 7 day trial procedure Patient patient 's legal representative provide write informed consent Patient agree comply followup evaluation Angiographic Inclusion Criteria Target lesion single de novo true bifurcation lesion ( Medina classification Type 1.1.1 ; 1.0.1 ; 0.1.1 ; 0.0.1 ) involve native coronary artery reference vessel diameter proximal main 2.5 5.0 mm , distal main 2.5 5.0 mm , &amp; side branch RVD 2.5 3.5 mm Target lesion main vessel stenosis &gt; 50 % &lt; 100 % Syntax score &lt; 32 General Exclusion Criteria Known hypersensitivity/contraindication aspirin , heparin bivalirudin , clopidogrel ticlopidine , cobalt , nickel , chromium , molybdenum , sensitivity contrast medium , ca n't adequately premedicated Platelet count &lt; 100,000 cells/mm³ &gt; 700,000 cells/mm³ , white blood cell ( WBC ) count &lt; 3,000 cells/mm³ within 7 day prior index procedure Serum creatinine level &gt; 170 micromol/L within 7 day prior index procedure Evidence acute MI within 72 hour intend trial procedure ( define : QWMI NQWMI CK enzymes &gt; 2X laboratory upper limit normal presence confirm cardiac specific biomarker ( Troponin I T ) Previous stenting anywhere target vessel Percutaneous coronary intervention ( PCI ) nontarget vessel within 30 day prior procedure result MAC ( C ) E event . If non target vessel stent implant within 72 hour prior index procedure , 2 post procedural serial CK CKMB measurement must investigational site 's upper limit normal PCI nontarget vessel within 24 hour prior procedure Planned PCI target vessel within 6 month postprocedure During index procedure , target lesion require treatment device PTCA cut balloon prior stent placement Documented leave ventricular ejection fraction ( LVEF ) &lt; 30 % recent evaluation History stroke transient ischemic attack ( TIA ) within prior 6 month Active peptic ulcer upper gastrointestinal ( GI ) bleeding within prior 6 month History bleed diathesis coagulopathy refuse blood transfusion Concurrent medical condition life expectancy &lt; 12 month Currently participate investigational drug device trial 's complete primary endpoint clinically interfere current trial endpoint ; require coronary angiography , IVUS coronary artery imaging procedure . Angiographic Exclusion Criteria Target lesion locate native vessel saphenous vein graft left/right internal mammary artery ( LIMA/RIMA ) bypass Target lesion follow characteristic : Severely calcify Evidence thrombus Syntax score ≥33</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Bifurcation coronary artery disease</keyword>
	<keyword>Percutaneous coronary intervention</keyword>
	<keyword>Tryton Stent</keyword>
</DOC>